IndicationsStatusPurposePhase
Unknown StatusTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT02325440Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya